NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 215 filers reported holding NEVRO CORP in Q4 2021. The put-call ratio across all filers is 1.68 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $451,670 | -15.0% | 23,500 | +12.4% | 0.00% | -20.0% |
| Q2 2023 | $531,278 | +126.1% | 20,900 | +221.5% | 0.01% | +150.0% |
| Q1 2023 | $234,975 | -10.1% | 6,500 | -1.5% | 0.00% | -33.3% |
| Q4 2022 | $261,360 | -31.6% | 6,600 | -19.5% | 0.00% | -25.0% |
| Q3 2022 | $382,120 | -39.2% | 8,200 | -5.7% | 0.00% | -33.3% |
| Q1 2022 | $629,000 | +14.2% | 8,700 | +27.9% | 0.01% | +50.0% |
| Q4 2021 | $551,000 | -16.9% | 6,800 | +19.3% | 0.00% | -42.9% |
| Q3 2021 | $663,000 | +48.0% | 5,700 | +111.1% | 0.01% | +75.0% |
| Q2 2021 | $448,000 | +52.9% | 2,700 | +28.6% | 0.00% | +33.3% |
| Q1 2021 | $293,000 | -39.6% | 2,100 | -25.0% | 0.00% | -40.0% |
| Q4 2020 | $485,000 | -58.5% | 2,800 | -66.7% | 0.01% | -61.5% |
| Q3 2020 | $1,170,000 | +112.7% | 8,400 | +82.6% | 0.01% | +116.7% |
| Q2 2020 | $550,000 | +41.0% | 4,600 | +17.9% | 0.01% | +20.0% |
| Q1 2020 | $390,000 | +57.9% | 3,900 | +85.7% | 0.01% | +66.7% |
| Q4 2019 | $247,000 | – | 2,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |